Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

PR Newswire May 9, 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

PR Newswire May 8, 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

PR Newswire May 1, 2024

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

PR Newswire April 11, 2024

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

PR Newswire March 28, 2024

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

PR Newswire March 25, 2024

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

PR Newswire March 7, 2024

Lipocine to Present at 36th Annual Roth Conference

PR Newswire March 6, 2024

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

PR Newswire February 6, 2024

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

PR Newswire February 2, 2024

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

PR Newswire January 18, 2024

Lipocine to Present at Biotech Showcase 2024

PR Newswire December 19, 2023

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

PR Newswire November 13, 2023

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

PR Newswire November 8, 2023

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

PR Newswire November 1, 2023

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

PR Newswire October 26, 2023

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

PR Newswire October 23, 2023

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 19, 2023

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

PR Newswire August 10, 2023

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

PR Newswire July 27, 2023